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Abstract Although apolipoprotein E3 (apoE3) is atheroprotec-
tive, two common isoforms, apoE2 and apoE4, produce recessive
and dominant hyperlipidaemias, respectively. Using a £uores-
cent assay, we report herein that apoE3 particles secreted
from recombinant cells stimulate more nitric oxide release in
cultured human EA.hy926 endothelial cells than apoE2 or
apoE4 (141% more than controls vs. 61 or 11%). Phosphatidyl-
inositol (PI) 3-kinase inhibitors suppressed the apoE e¡ect,
while apoE receptor 2 (apoER2) was tyrosine phosphorylated.
We conclude that apoE stimulates endothelial nitric oxide re-
lease in an isoform-dependent manner, and propose that tyrosine
phosphorylation of apoER2 initiates PI3-kinase signalling and
activation of nitric oxide synthase.
- 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Apolipoprotein E (apoE) is a 34-kDa polypeptide synthe-
sised predominantly by the liver and helps protect against
atherosclerosis, in part by mediating hepatic clearance of rem-
nant plasma lipoproteins [1,2]. When apoE is absent or dys-
functional, severe hyperlipidaemia and atherosclerosis ensue,
while infusion of apoE or hepatic gene overexpression are
protective [3^5]. ApoE has three common isoforms that arise
from single nucleotide polymorphisms [1,2]. The rarest var-
iant, apoE2, di¡ers from wild-type apoE3 by an Arg158Cys
substitution and causes Type III hyperlipidaemia [6], while
apoE4 (Cys112Arg) produces a dominant hyperlipidaemia
and is a risk factor for restenosis [7] and smoking-related
heart disease [8].
ApoE is also abundant in atherosclerotic lesions, secreted
by resident cholesterol-loaded macrophages [9]. This locally
produced apoE is atheroprotective by contributing to reverse
cholesterol transport [10,11], inhibiting smooth muscle cell
proliferation [12], preventing oxidation [13], and restricting
platelet aggregation [14]. In platelets, the binding of apoE
by apoE receptor 2 (apoER2) appears to initiate a signal
transduction cascade to upregulate nitric oxide synthase
(NOS) [14^16]. Moreover, we have recently reported that in
human umbilical vein endothelial cells (HUVECs), cell-de-
rived apoE inhibits expression of vascular cell adhesion mol-
ecule-1 (VCAM-1) [17], a key pro-atherogenic molecule in-
volved in the recruitment of monocytes to lesions [18,19].
Suppression of endothelial activation by apoE occurred via
stimulation of NOS, and we proposed that apoE secreted
locally at lesion sites by macrophages is anti-in£ammatory
by stimulating the endothelium to release NO and suppress
VCAM-1 expression [17].
Here, we have studied the apoE-NO link in EA.hy926 cells,
a hybrid cell line derived by fusion of HUVECs with A549
epithelial cells [20], which is known to retain many of the
di¡erentiated functions characteristic of endothelial cells [20^
23]. We con¢rm that apoE stimulates endothelial NO release
by incubating EA.hy926 cells with conditioned medium from
recombinant Chinese hamster ovary (CHO) cells that secrete
apoE particles, similar to those secreted by macrophages [17].
We then show that the three apoE isoforms have a di¡erential
ability to stimulate NO release by using media from
CHOapoE2=3=4 cells secreting apoE2, apoE3 and apoE4 par-
ticles, respectively, and report a heterogeneity in apoE particle
size that may in£uence this activity. Finally, we implicate
phosphatidylinositol (PI) 3-kinase signalling in apoE-induced
NOS activation and suggest that this pathway is activated by
tyrosine phosphorylation of cytoplasmic apoER2 upon endo-
thelial exposure to apoE.
2. Materials and methods
2.1. Cell culture
EA.hy926 human endothelial cells were generously provided by Dr
Edgell, University of North Carolina and were maintained in DMEM
media supplemented with 10% (v/v) fetal bovine serum (FBS), 100 IU/
ml penicillin, 100 Wg/ml streptomycin, 0.1 mM sodium hypoxanthine,
0.4 WM aminopterin and 16 WM thymidine. Recombinant CHO cells
stably secreting human apoE2, apoE3 or apoE4 isoforms (CHOapoE2,
CHOapoE3 and CHOapoE4 cells) were produced as described elsewhere
[24]. They were maintained in Iscove’s selection media plus 2 mM
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Glutamax and 10% (v/v) dialysed FBS, while media for control
CHOdhfr cells was supplemented with 0.1 mM hypoxanthine and
16 WM thymidine [24]. Cell-conditioned media was collected by incu-
bating CHOapoE2, CHOapoE3, CHOapoE4 or CHOdhfr cells (each
V80% con£uent) for 24 h in M199 media containing 5% (v/v) FBS
when the yields were typically 8, 4 and 2 Wg apoE/ml, respectively.
The apoE media were adjusted to contain the same amount of apoE
by addition of CHOdhfr-conditioned medium and, after concentrat-
ing three-fold in Vivaspin concentrators (30 000 molecular weight cut
o¡; Vivaspin Ltd, Lincoln, UK), sterile ¢ltered (0.2 WM).
2.2. Intracellular NO measurement
Intracellular endothelial NO production was measured directly in
triplicate wells using the cell-permeable £uorescent indicator 4,5-dia-
mino£uorescein diacetate (DAF-2 DA; Calbiochem, Nottingham,
UK) [25]. Con£uent EA.hy926 cells in 48-well plates were incubated
with 10 WM DAF-2 DA for 1 h at 37‡C. To inhibit NOS activity,
wells were pre-incubated for 2 h with 20 WM 2-ethyl-2-isothiopseu-
dourea (ethyl-ITU; Alexis Corporation Ltd, Nottingham, UK) [26].
Other wells were pre-incubated for 1 h with either wortmannin (50^
200 nM range; Calbiochem, Nottingham, UK) or LY294002 (5^20
WM range; Sigma) prior to addition of DAF-2 DA. Monolayers were
washed with warm phosphate-bu¡ered saline (PBS) and then incuba-
ted with CHO cell-conditioned media (from either CHOapoE2,
CHOapoE3, CHOapoE4 or CHOdhfr cells) with some wells supple-
mented with 20 WM ethyl-ITU, 50^200 nM wortmannin or 5^20
WM LY294002. Fluorescent emissions at 530 nm (bandwidth of 25
nm) were read using a Cyto£uor Series 400 plate reader (PerSeptive
Biosystems, Framingham, MA, USA) upon excitation at 485 nm
(bandwidth of 20 nm). Results are expressed as change in relative
DAF-2 DA £uorescence (arbitrary units) over a 4 h time course as
a percentage of the £uorescence signal from control wells treated with
CHOdhfr cell-conditioned media.
2.3. Electrophoretic characterisation of apoE particles
ApoE particles in CHO cell-conditioned media (from CHOapoE2,
CHOapoE3 and CHOapoE4 cells) were analysed for electrophoretic mo-
bility in agarose hydragels (Sebia, Issy-les-Moulineanx, France) using
immunoblotting for detection [17]. In addition, particle diameter was
assessed by non-denaturing gel electrophoresis (NDGE) on a 20%
Tris^borate (pH 8.3) mini-gel (Invitrogen, The Netherlands) that
had been pre-run at 100 V for 30 min at 4‡C. Native high molecular
weight protein standards (Amersham Biosciences UK Ltd, Little
Chalfont, UK) were used as size standards [27]. Non-boiled and
non-reduced samples were loaded in a bu¡er containing 10% sucrose
and 0.016% bromophenol blue. Electrophoresis was performed with
the following step-wise voltage scheme: 25 V for 15 min, 50 V for 15
min, 75 V for 15 min and then 100 V for 18 h whilst being maintained
at 4‡C. Proteins were blotted to a nitrocellulose membrane and
probed with polyclonal goat anti-human apoE antibody (DiaSorin
Inc., Stillwater, MN, USA). Immunoreactive bands were visualised
by enhanced chemiluminescence (Amersham Biosciences UK Ltd),
while native molecular size standards were detected by Coomassie
staining the gel.
2.4. Quanti¢cation of apoE by enzyme-linked immunosorbent assay
(ELISA)
ApoE concentration in CHO cell-conditioned media was measured
by a two-antibody sandwich ELISA [5]. Brie£y, polyclonal goat anti-
human apoE antibodies were used both for capture (DiaSorin Inc.)
and, after biotinylation using a commercial kit (Amersham Bioscien-
ces UK Ltd), for detection (Biogenesis Ltd, Poole, Dorset, UK). Hu-
man serum containing a known amount of apoE was used as a stan-
dard (Technoclone Ltd, Dorking, UK). Standard and media samples
were diluted in assay bu¡er; 150 mM NaCl, pH 7.4 containing 0.5%
(w/v) bovine serum albumin, 0.05% (w/v) gamma-globulin, 0.01%
(v/v) Tween 40 and 50 mM Tris.
2.5. Identi¢cation of apoER2 in EA.hy926 cells
EA.hy926 cells were incubated for 4 h with either CHOdhfror
CHOapoE2 cell-conditioned media, washed with PBS (4‡C) and then
lysed with lysis bu¡er [1% (v/v) Triton X-100, 50 mM Tris (pH 7.5),
150 mM NaCl, 1 mM EDTA and protease inhibitor cocktail tablets
(Complete1 ; Roche Diagnostics, Welwyn Garden City, UK)], supple-
mented with 1 mM dithiothreitol and 1 mM sodium orthovanadate.
Lysates were clari¢ed and the supernatant precleared for 90 min with
anti-rabbit IgG-coated Dynabeads (Dynal, Bromborough, UK). The
cleared sample was then incubated overnight at 4‡C with rabbit anti-
apoER2 antisera directed against a cytoplasmic tail sequence common
to all splice variants [16] (1:100 dilution) and then with anti-rabbit
IgG-coated Dynabeads for 90 min. Immunocomplexes were collected,
washed with lysis bu¡er and boiled in sodium dodecyl sulphate^poly-
acrylamide gel electrophoresis (SDS^PAGE) sample bu¡er. Proteins
were separated by 8% or 4^20% gradient SDS^PAGE, transferred to
nitrocellulose and immunoblotted for either phosphotyrosine using
polyclonal anti-phosphotyrosine (PY20; Zymed Laboratories, San
Francisco, CA, USA) or for apoER2 using goat polyclonal anti-
apoER2 (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA).
To con¢rm that apoER2 was present in plasma membranes, con-
£uent EA.hy926 cell monolayers were washed with warm PBS and
cell-surface proteins biotinylated using sulpho-NHS-LC-biotin at 0.5
mg/ml (Pierce, Tattenhall, UK) for 30 min at room temperature. Cells
were then washed, incubated with 10 mM glycine for 20 min to
quench any unbound biotin and lysed. Samples were clari¢ed by cen-
trifugation and the supernatants were incubated with streptavidin
beads (Sigma) for 2 h at 4‡C on a rotating wheel, after which time
the beads were washed with lysis bu¡er and then boiled in SDS^
PAGE bu¡er. Proteins were separated by 8% SDS^PAGE, transferred
to nitrocellulose and probed for apoER2 using our own rabbit poly-
clonal anti-apoER2 antibody (anti-apoER2Ins) [15].
2.6. Statistical analysis
Statistical analysis for n=3 independent experiments, which were
done in triplicate for each point in the data, was performed using
Student’s t-test. The results are shown as meanTS.E. of the mean
values from the three independent experiments and P6 0.05 was con-
sidered signi¢cant.
3. Results
3.1. ApoER2 and eNOS are expressed in the EA.hy926 human
endothelial cell line
ApoER2 is localised to caveolae signalling microdomains
within plasma membranes [16] ; it is thought to be an ‘out-
side-in’ signal transducer in brain (28^30) and to mediate
apoE-NO signaling in platelets and endothelial cells [15^
17,31]. ApoER2 di¡ers from other members of the low-den-
sity lipoprotein receptor (LDL-R) gene family by having sev-
eral splice variants in mRNA from human tissues [32^34].
Here, we have immunoprecipitated whole cell lysates to detect
apoER2 protein in the hybrid HUVEC^epithelial cell line,
Fig. 1. ApoER2 and eNOS are expressed in EA.hy926 cells. A: Im-
munoprecipitation of EA.hy926 cell lysate with antisera against the
cytoplasmic tail of apoER2 veri¢ed that apoER2v4^6 (132 kDa)
was expressed and also a smaller amount of full-length apoER2
(180 kDa). B: Western blotting of cell lysates con¢rmed expression
of eNOS (140 kDa).
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EA.hy926 (Fig. 1A). Two bands were detected, a major one at
132 kDa corresponding to apoER2v4^6 (receptor lacking li-
gand-binding repeats 4^6) and a minor one at 180 kDa rep-
resenting the full-length receptor. When cell-surface expres-
sion of the receptor was monitored, using the biotinylation
of intact cells [15], the 132-kDa band was also the predom-
inant form (data not shown). To con¢rm that EA.hy926 cells
express eNOS, cell lysates were immunoblotted with anti-
eNOS; the predicted immunoreactive band at 140 kDa was
detected (Fig. 1B).
3.2. ApoE stimulates NO production in EA.hy926 endothelial
cells
Intracellular NO production in EA.hy926 cells was mea-
sured directly using the cell-permeable £uorescent indicator,
DAF-2 DA. This reagent is hydrolysed intracellularly to the
active form, DAF-2, which then reacts with NO to produce
highly £uorescent DAF-2T (triazolo£uorescein). Measure-
ment of DAF-2T includes the simultaneous detection of
DAF-2 and, although its contribution is negligible when NO
production is high, in systems such as endothelial cells with
low NO output, DAF-2 auto-£uorescence may contribute sig-
ni¢cantly to the signal; the cells themselves and media may
also contribute. Indeed, the basal production of NO by
EA.hy926 cells appeared negligible; when we added the
NOS inhibitor, ethyl-ITU, the signal was not reduced, imply-
ing that it was derived from the combined auto-£uorescent
background of DAF-2, cells and media rather than NO
(Fig. 2).
To investigate e¡ects of apoE on release of NO by
EA.hy926 cells, we initially used conditioned media from
CHOapoE2 cells ; this clone was our highest producing cell
line (V8 Wg apoE/ml/24 h), while any role for the LDL-R-
related protein can be discounted as both these receptors bind
apoE2 poorly [17]. During a 4 h incubation with CHOapoE2
cell-conditioned media containing 17.3T 2.6 Wg apoE/ml, the
£uorescent signal increased by almost 50% above basal levels,
from 100.0 T 4.2% in EA.hy926 cells incubated with control-
conditioned media to 146.7T 2.0% (P6 0.001, n=3) (Fig. 2).
Moreover, this e¡ect was completely blocked by pretreating
the cells with the NOS inhibitor, ethyl-ITU (P6 0.001, n=3),
con¢rming that the increased signal was due to NO release.
3.3. NO production is dependent on apoE isoform
To compare the NO production stimulated by di¡erent iso-
forms of apoE in parallel wells, media were collected from
Fig. 2. ApoE stimulates NO production in EA.hy926 cells. Intracel-
lular NO production was measured directly using a £uorescent
DAF-2 DA assay. There was a 46.7T 2.0% increase in NO from
basal levels of 100.0T 4.2% (in EA.hy926 cells exposed to controlled
conditioned media) to 146.7T 2.0% (*P6 0.001, n=3) during a 4 h
incubation with CHOapoE2 cell-conditioned media containing
17.3T 2.6 Wg apoE/ml. This increase was blocked by pre-incubation
with 20 WM of the NOS inhibitor, ethyl-ITU (*P6 0.001, n=3). Re-
sults are expressed as a percentage of the relative £uorescence (arbi-
trary units) in wells treated with control CHOdhfr cell-conditioned
media. Data are shown from three independent experiments per-
formed in triplicate using three di¡erent preparations of cell-condi-
tioned media.
Fig. 3. Production of NO is apoE isoform dependent. A: EA.hy926
cells were incubated with cell-conditioned media containing approxi-
mately equal concentrations of apoE2, apoE3 or apoE4 (2.7T 0.4,
2.8 T 0.5, 2.8 T 0.3 Wg apoE/ml, respectively) for 4 h, and intra-
cellular NO production was measured using a £uorescent DAF-2
DA assay. ApoE3 caused the greatest increase in NO release
(141.0T 6.9%, *P6 0.001, n=3) over the control baseline of
100.0T 5.2%, while the increase caused by apoE2 was less pro-
nounced (61T 5.3% over control, *P6 0.01, n=3). In marked con-
trast, apoE4 did not signi¢cantly increase NO production
(11.0 T 2.8%, Ps 0.05, n=3). Results are expressed as a percentage
of the relative DAF-2 DA £uorescence (arbitrary units) in wells
treated with CHOdhfr cell-conditioned media. Data are from three
independent experiments performed in triplicate, with parallel wells
for each isoform, using three di¡erent preparations of cell-condi-
tioned media. B: ApoE particles secreted from CHOapoE2=3=4 cells
were separated by native agarose gel electrophoresis and immuno-
blotted for apoE. Equal amounts of apoE were used for each iso-
form. The mobility of particles was compared to a sample of hu-
man plasma. Most cell-derived apoE particles had pre-K mobility.
C: ApoE particles from CHOapoE2, CHOapoE3 and CHOapoE4 cell-
conditioned media (all at approximately 2.9 Wg apoE/ml) were char-
acterised by NDGE using immunoblotting for detection. Hydrated
diameters were compared to native high molecular weight standards.
Three main particle populations with diameters of 7.6, 8.0 and 10.4
nm could be identi¢ed, but were distributed heterogeneously be-
tween the di¡erent apoE isoforms.
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CHOapoE2, CHOapoE3 and CHOapoE4 cells and added to the
EA.hy926 cells at equivalent concentrations (2.7 T 0.4,
2.8 T 0.5 and 2.8T 0.3 Wg apoE/ml, respectively) as measured
by apoE ELISA. Over the 4 h incubation, apoE3 caused the
greatest increase (141T 6.9%) in NO release over control me-
dia (P6 0.001, n=3, Fig. 3A), with apoE2 stimulating less
than half the increase of apoE3 (61.0 T 5.3%, P6 0.01,
n=3). In contrast, apoE4 did not stimulate a signi¢cant in-
crease in NO production (11.0 T 2.8%, Ps 0.05, n=3).
3.4. Characterisation of apoE particles
Previously, we have shown that the apoE particles secreted
by recombinant CHO cells have several similarities to those
secreted by human blood monocyte-derived macrophages [17].
They were spheres of a similar diameter, as judged by negative
scanning electron microscopy, and had comparable pro¢les by
agarose gel electrophoresis and gel ¢ltration [17]. Here, we
have directly compared the apoE particles secreted from
CHOapoE2=3=4 cells using agarose gel electrophoresis and
apoE immunoblotting. Most of the cell-derived apoE particles
had pre-K mobility, and all three isoforms gave similar pat-
terns (Fig. 3B). However, some di¡erences between the iso-
forms were noted when equal amounts of apoE were analysed
using NDGE. Three main apoE particle populations were
identi¢ed with hydrated diameters of 7.6, 8.0 and 10.4 nm
(Fig. 3C). The 7.6 nm particle was common to all three iso-
forms but appeared to be less abundant in the apoE2 sample.
The 8 nm particle was common to apoE2 and apoE3, though
more prominent in the apoE3 sample, but appeared to be
completely absent from apoE4 media. The 10.2 nm particle
was present in each sample, although much lower in apoE3
media.
3.5. Inhibitors of PI3-kinase partially suppress apoE-induced
release of NO
Wortmannin is an irreversible inhibitor of PI3-kinase at low
concentrations [35]. Pretreatment of EA.hy926 cells with wort-
mannin (50^200 nM) caused a dose-dependent inhibition of
NO release when cells were incubated with 16.9T 2.1 Wg/ml
apoE2 for 4 h (Fig. 4A). NO production is shown as a per-
centage of the NO response produced by apoE alone (above
the level of the control-conditioned media) normalised to
100% (100.0 T 3.2%, n=3). Cells incubated with 50 and 100
nM wortmannin had production of NO inhibited by
26.3T 2.9% and 39.6T 2.4%, respectively (both P6 0.001,
n=3). Further inhibition of apoE-stimulated NO release
(73.8 T 3.6%, P6 0.001, n=3) was detected using 200 nM
wortmannin. However, at this higher dose, wortmannin is
not a speci¢c inhibitor of P13-kinase, and inhibition of NO
could be due to e¡ects on other signalling pathways, such as
the mitogen-activated protein (MAP) kinase pathway [36].
LY294002 is a speci¢c PI3-kinase inhibitor which acts at
the ATP-binding site of the enzyme [37]. Pretreatment of
EA.hy926 cells with LY294002 (5^20 WM) caused an inhibi-
tion of NO production when cells were incubated with
15.8T 2.3 Wg apoE/ml for 4 h (Fig. 4B). Cells incubated
with 5 and 10 WM LY294002 showed apoE-induced NO pro-
duction inhibited by 17.9 T 5.6% and 37.6 T 4.1%, respectively
(both P6 0.001, n=3). A higher dose of inhibitor did not
cause any additional inhibition of NO production indicating
that a maximal e¡ect had been reached; 20 WM LY294002 led
to a decrease in NO production by apoE of 39.1T 4.2%
(P6 0.001, n=3). This inhibition was comparable to that
achieved by using 100 nM wortmannin (39.6 T 2.4%).
3.6. ApoER2 is tyrosine phosphorylated upon exposure to apoE
ApoER2 has two tyrosine residues within its cytoplasmic
tail. To investigate tyrosine phosphorylation of cytoplasmic
apoER2 as a potential signalling step, EA.hy926 cells were
exposed to apoE for 0, 2.5, 5 and 10 min. Cells were then
lysed, immunoprecipitated for apoER2 and immunoblotted
for phosphotyrosine. Equal amounts of protein were loaded
Fig. 4. P13-kinase inhibitors suppress apoE-induced NO production.
A: EA.hy926 cells were pre-incubated with the general kinase inhib-
itor, wortmannin (50^200 nM), and then incubated with conditioned
media containing 16.9T 2.1 Wg apoE2/ml for 4 h. NO release was
monitored using the £uorescent DAF-2 DA assay and data are
shown as ‘NO production as a percentage of maximal apoE re-
sponse’ (values from control cell-conditioned media were subtracted
from all data and the maximal apoE response was normalised to
100%; 100.0T 3.2%, n=3). ApoE-induced NO production was in-
hibited by 26.3T 2.9%, 39.6T 2.4% and 73.8T 3.6% when cells were
incubated with 50, 100 and 200 nM wortmannin, respectively (all
*P6 0.001, n=3). B: EA.hy926 cells were pretreated with the spe-
ci¢c PI3-kinase inhibitor, LY294002 (5^20 WM), and then incubated
with conditioned media containing 15.8T 2.3 Wg apoE2/ml for 4 h.
ApoE-induced NO response was 100.0T 3.7% (n=3) and was inhib-
ited by 17.9T 5.6%, 37.6T 4.1% and 39.1T 4.2% when cells were in-
cubated with 5, 10 and 20 WM LY294002, respectively (all
*P6 0.001, n=3). Data sets shown in both A and B were from
three independent experiments performed in triplicate using three
di¡erent preparations of cell-conditioned media.
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in each lane and this was con¢rmed by immunoblotting for
apoER2. EA.hy926 cells were also treated in parallel with
control-conditioned media from CHOdhfr cells; no change
in the level of tyrosine phosphorylation was detected (Fig.
5A). In contrast, exposure to apoE2 (16.3 T 2.2 Wg apoE/ml)
caused an increase in tyrosine phosphorylation above the level
in resting cells. Maximal tyrosine phosphorylation was de-
tected by 2.5 min which then began to decrease at 5 min, until
phosphorylation levels returned to those in resting cells by 10
min (Fig. 5B).
4. Discussion
This study in EA.hy926 cells con¢rms our earlier report,
carried out in a di¡erent model of human endothelial cells,
HUVECs, that apoE activates NOS to release NO [17]. In
extending this work, we now report a marked di¡erential
isoform e¡ect on stimulating NO production with apoE3s
apoE2EapoE4, a ¢nding consistent with the potential of
apoE2 and apoE4 to confer increased risk for developing
coronary heart disease [2,7,38]. In addition, we have impli-
cated tyrosine phosphorylation of apoER2 and PI3-kinase
signalling as being involved in apoE-mediated activation of
eNOS.
The EA.hy926 cell line is a hybrid of primary HUVECs
fused with A549 epithelial cells [20], which perform many of
the di¡erentiated functions characteristic of endothelial cells,
such as angiogenesis, haemostasis, and in£ammation [20^23].
They have been used before in NO signalling studies [21] and,
importantly, in future studies they will be easier to manipulate
genetically than primary cells. We con¢rmed that EA.hy926
cells expressed eNOS protein and, as we had previously im-
plicated apoER2 as the receptor mediating apoE-induced re-
lease of NO in HUVECs [17], screened for this protein using
two di¡erent immunological techniques. We found that
EA.hy926 cells expressed two forms of the receptor; as in
HUVECs the splice variant lacking ligand-binding repeats
4^6, apoER2v4^6, predominated. Moreover, when we incu-
bated EA.hy926 cells with apoE2-containing conditioned me-
dia from CHOapoE2 cells, we found a clear increase in NO
production, as previously reported in HUVECs [17]. This re-
sponse was due to activation of eNOS, since the inhibitor
ethyl-ITU blocked the e¡ect.
Recombinant cell-secreted apoE has biological activities
similar to native apoE [17,39] and, therefore, any di¡erence
in the ability of apoE isoforms to activate eNOS might be
relevant to susceptibility to certain diseases. ApoE2 is the
genetic cause of Type III hyperlipidaemia, but protects against
Alzheimer’s disease [40] ; apoE4 is a risk factor for restenosis
[7] and smoking-related heart disease [8], and is strongly
linked to late-onset Alzheimer’s disease and other neurode-
generative diseases [40^43]. Intriguingly, these two isoforms
stimulated less production of NO than wild-type apoE3. In-
deed, apoE2 stimulated less than half the NO released by
apoE3, while apoE4 failed to signi¢cantly increase NO levels
above the control. NO has multiple atheroprotective e¡ects
[44^46], some of which are common to apoE including inhi-
bition of platelet adhesion and aggregation [28,47], smooth
muscle proliferation and migration [12,48,49], and inhibition
of endothelial cell adhesion molecules [17,50]. NO is also an
important molecule in the brain, acting as an intracellular
messenger, regulating blood £ow and contributing to morpho-
genesis and neuronal plasticity [51]. It is also crucial for neu-
rite outgrowth [52] and, as this process is impaired in Alz-
heimer’s disease [53] it will be of interest to test whether apoE
isoforms di¡er in their ability to stimulate NOS in neuronal
cells.
We propose that some of the di¡erential e¡ects of apoE
isoforms on eNOS activation may re£ect heterogeneity in se-
creted particles, rather than protein sequence per se. ApoE
conformation and receptor binding activity are markedly in-
£uenced by lipid environment and particle characteristics
[39,54]. Characterisation of apoE in CHOapoE2=3=4 cell media
revealed that although the majority of particles had pre-K
mobility, a particle population of 8 nm in diameter was prom-
inent in apoE3 media, less abundant in apoE2 media and
absent in apoE4 media. Further experiments are needed to
establish whether the 8 nm apoE-containing particles are the
active cell-derived factors that stimulate the release of NO.
A variety of signal transduction cascades activate eNOS,
including the P13-kinase pathway [55]. We found that wort-
mannin, and the speci¢c inhibitor of PI3-kinase, LY294002,
consistently suppressed release of NO from apoE-stimulated
endothelial cells. However, this inhibition was not complete; a
maximal inhibition of V40% was achieved by LY294002,
with higher doses unable to block further NO release. By
Fig. 5. ApoER2 is tyrosine phosphorylated upon exposure to apoE. EA.hy926 cells were incubated with conditioned media from either
CHOdhfr (A) or CHOapoE2 (B) cells for up to 10 min. At each time point, cells were lysed and apoER2 isolated by immunoprecipitation. The
immunoprecipitates were separated by 8% SDS^PAGE gel and immunoblotted for apoER2 and phosphotyrosine (PY20). Equal amounts of
protein were loaded in each lane and this was con¢rmed by immunoblotting for apoER2. A: EA.hy926 cells incubated with control cell-condi-
tioned media from CHOdhfr cells showed no change in tyrosine phosphorylation. B: Incubation with apoE, however, stimulated tyrosine phos-
phorylation. The peak level was seen at 2.5 min, which then began to decrease at 5 min until phosphorylation levels returned to those in rest-
ing cells by 10 min.
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contrast, higher doses of wortmannin, which are known to
block other signalling enzymes in addition to PI3-kinase, in-
cluding MAP kinase, myosin light chain kinase, PI4-kinase
and phospholipase D [56], did cause further inhibition. This
suggests that more than one pathway might relay the apoE-
triggered signal for activating eNOS.
The initial step most likely involves binding of apoE by
apoER2 [15,57], although we cannot entirely exclude involve-
ment of other LDL-R family members or heparan sulphated
proteoglycans [2,58], and we report herein that endothelial
apoER2 was rapidly tyrosine phosphorylated when cells
were exposed to apoE. Although apoER2 has homology to
other members of the LDL-R family, its cellular role is un-
likely to involve lipoprotein uptake and degradation [30,59].
Indeed, the cytoplasmic sequence NPxY, common to all LDL-
R family members and originally identi¢ed as the recognition
motif for endocytosis [60], also serves as a ligand for the
phosphotyrosine binding and PDZ domains of signalling mol-
ecules [60]. Current evidence implicates apoER2 as a signal
transducer molecule, regulating neuronal cell migration dur-
ing brain development [28^30,60,61], and suppressing platelet
aggregation in the vasculature [15,16,31]. Signalling appears
to require interaction between cytoplasmic apoER2 and
adapter molecules [28^30,60,61] and crucially apoER2 and
intermediates of potential signalling cascades, including
eNOS, are present in specialised plasma membrane microdo-
mains, caveolae [16,62]. Cytoplasmic apoER2 contains two
tyrosine residues, though as yet we do not know which resi-
due(s) are phosphorylated. It is tempting, however, to spec-
ulate that this apoE-induced phosphorylation event may con-
stitute an early step in an ‘outside-in’ signal transduction
cascade that involves P13-kinase and ends in eNOS activa-
tion. Clearly, further work is needed to verify this possibility
and to delineate the rest of the signalling pathway.
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